CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
[68Ga]Ga-OncoACP3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06840535
NCT06840535Phase 1Completed
CompareCT.gov

A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

Philogen S.p.A.·interventional·Posted Feb 21, 2025·Updated Jan 6, 2026

In Brief

A Phase 1 clinical trial evaluating [68Ga]Ga-OncoACP3 for Prostate Cancer and 2 related conditions. Completed, enrolled 20 participants across 3 sites.

Detailed Summary

The aim of this study is to assess the safety and dosimetry of \[68Ga\]Ga-OncoACP3 in patients with prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2
CountriesItaly
Collaborators--

Timeline

Phase 1CompletedFinished
2026
First PostedFeb 21, 2025
Enrollment StartApr 8, 2025
Primary CompletionOct 3, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.4 years ago

Interventions

[68Ga]Ga-OncoACP3drug

Single intravenous bolus injection.